Cargando…
Peptide Platform as a Powerful Tool in the Fight against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a global pandemic causing over 195 million infections and more than 4 million fatalities as of July 2021.To date, it has been demonstrated that a number of mutations in the spike glycoprotein (S protein) of SARS-CoV-2 varia...
Autores principales: | Murdocca, Michela, Citro, Gennaro, Romeo, Isabella, Lupia, Antonio, Miersch, Shane, Amadio, Bruno, Bonomo, Alessia, Rossi, Antonio, Sidhu, Sachdev S., Pandolfi, Pier Paolo, Alcaro, Stefano, Sangiuolo, Federica Carla, Novelli, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402770/ https://www.ncbi.nlm.nih.gov/pubmed/34452531 http://dx.doi.org/10.3390/v13081667 |
Ejemplares similares
-
Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids
por: Spitalieri, Paola, et al.
Publicado: (2022) -
COVID-19: S-Peptide RBD (484–508) Induces IFN-γ T-Cell Response in Naïve-to-Infection and Unvaccinated Subjects with Close Contact with SARS-CoV-2-Positive Patients
por: Murdocca, Michela, et al.
Publicado: (2023) -
Intracellular targeting with engineered proteins
por: Miersch, Shane, et al.
Publicado: (2016) -
Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine
por: Novelli, Giuseppe, et al.
Publicado: (2023) -
Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets
por: Romeo, Isabella, et al.
Publicado: (2021)